Joseph Drabick

Joseph Drabick serves as Professor and Rose Dunlap Division Chief Chair in Hematology/Oncology within the Department of Medicine at Penn State College of Medicine and the Penn State Cancer Institute. His academic leadership extends to the Cancer Institute's Next-Generation Therapies program, reflecting his significant contributions to oncological research and clinical practice.

Dr. Drabick's research interests focus on malignant neoplasms, with particular expertise in melanoma, metastatic melanoma, and immunotherapy approaches. His work spans radiation therapy applications, overall survival analysis, and innovative treatment strategies for hematological malignancies. The research fingerprint analysis reveals his strong contributions to understanding tumor biology and therapeutic responses across multiple cancer types.

His scholarly impact is evidenced by an h-index of 32 with 4,712 citations, reflecting substantial influence in the oncology field. Dr. Drabick maintains an active publication record with 136 research outputs spanning from 1985 to the present, demonstrating sustained scholarly productivity over nearly four decades.

• Fellow, American College of Physicians (FACP)
• Rose Dunlap Division Chief Chair in Hematology/Oncology

Dr. Drabick has led significant research initiatives, most notably serving as Principal Investigator for the Cancer and Leukemia Group B project funded by the National Cancer Institute from 1985 to 2003. This extensive clinical research program focused on leukemia treatment, patient accruals, and malignant neoplasm studies across multiple medical centers. His collaborative network extends internationally, with research activities spanning multiple countries as indicated by the global collaboration map.

As Division Chief, Dr. Drabick oversees clinical and research operations within Hematology/Oncology, directing the Next-Generation Therapies program at the Penn State Cancer Institute. His leadership integrates clinical care with innovative research approaches, particularly in the areas of immunotherapy and targeted cancer treatments.